December 2018 - Clinical trial listings - locations, diseases, sponsors -

Clinical Trials for Oxymorphone Hydrochloride

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00225797	Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain	Completed	Endo Pharmaceuticals	Phase 3	The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.
NCT00226395	Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain	Completed	Endo Pharmaceuticals	Phase 3	The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
NCT00226421	Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain	Completed	Endo Pharmaceuticals	Phase 3	The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
NCT00260260	OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain	Completed	Odense University Hospital	Phase 4	Patients undergoing surgery (thyroidectomy and hysterectomy) will postoperatively receive oxycodone intravenously (IV) as pain management with morphine as an escape medicine, if there is insufficient pain relief with oxycodone. Patients' pain and side effects will be registered and after 24 hours they will answer a questionnaire. All included patients will be genotyped accordingly to CYP2D6 and relevant single nucleotide polymorphisms (SNPs), and measures of plasma levels of oxycodone will be performed.
NCT00271973	OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models	Completed	Odense University Hospital	Phase 4	Thirty-two healthy volunteers will be submitted to experimental pain and on the 2 study days receive Oxycodone 20 mg po vs. placebo. Half of the volunteers will be poor metabolizers according to CYP2D6 genotype and half will be extensive metabolizers (EM) and have an enzyme with normal function. The study hypothesis is that PM will experience less pain relief than EM.
NCT00580294	A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)	Completed	Endo Pharmaceuticals	N/A	The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients. This study will examine if the switching from one pain medication to another can be done over a 24 hour period. Oxymorphone, the drug being studied, is an FDA approved drug for treatment of severe pain.
Trial ID	Title	Status	Sponsor	Phase	Summary